Telisotuzumab ABT-700|cas:1781223-80-0|西域试剂

Telisotuzumab ABT-700,95.0%

产品编号：Bellancom-P99391| CAS NO：1781223-80-0

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99391		￥4500.00	杭州北京（现货）
Bellancom-P99391		￥11250.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Telisotuzumab ABT-700

产品介绍

Telisotuzumab (ABT-700) 是一种人源化重组二价抗体，针对肝细胞生长因子受体（MET）的治疗性抗体，可以高亲和力结合 c-Met 并抑制 c-Met 信号传导。Telisotuzumab 具有抗肿瘤活性。

生物活性

Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity.

体外研究

Telisotuzumab (ABT-700) (10 μg/mL, 24 h) 可以抑制 SNU5 细胞的增殖，并导致促凋亡的 Bim 增加和抗凋亡的 Bcl-xL 减少，从而诱发细胞凋亡。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) 有效拮抗构成性激活的 c-Met 和下游信号，从而抑制 Hs746T 细胞 SCID 小鼠的肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice with Hs746T cells
Dosage:	2.5-40 mg/kg
Administration:	i.p., twice a week, 90 days
Result:	Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk. Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.

体内研究

Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) 有效拮抗构成性激活的 c-Met 和下游信号，从而抑制 Hs746T 细胞 SCID 小鼠的肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice with Hs746T cells
Dosage:	2.5-40 mg/kg
Administration:	i.p., twice a week, 90 days
Result:	Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk. Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.